Transient receptor potential channels and dermatological disorders

Current Topics in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 335-343

  Valdes Rodriguez, Rodrigo ^a   Kaushik, Shivani B ^a   Yosipovitch, Gil ^a,b  

^a Department of Neurobiology and Anatomy ^*  (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Hair growth; Itch; Skin barrier; Skin cancers; TRPA; TRPC; TRPM; TRPML; TRPV

Indexed keywords

CAPSAICIN; N (4 ISOPROPYLPHENYL) 2 (1, 2, 3, 6 TETRAHYDRO 1, 3 DIMETHYL 2, 6 DIOXO 7H PURIN 7 YL) ACETAMIDE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR 3; VANILLOID RECEPTOR 4; VANILLOID RECEPTOR 6;

APOPTOSIS; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CALCIUM TRANSPORT; CONTACT DERMATITIS; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; KERATINOCYTE; MELANOMA; NEURODERMATITIS; NEUROGENIC INFLAMMATION; NONHUMAN; OSMOTIC PRESSURE; PSORIASIS; REVIEW; ROSACEA; SKIN DISEASE; VASODILATATION;

ANIMALS; HUMANS; SKIN DISEASES; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84876727400     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266112129990090     Document Type: Review

References (82)

1. Minke B, Cook B. TRP channel proteins and signal transduction. Physiol. Rev. 2002, 82(2), 429-72.
2. Moran MM, McAlexander MA, Bíró T, Szallasi A Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug. Discov. 2011, 10(8), 601-20.
3. Venkatachalam K, Montell C. TRP channels. Annu. Rev. Biochem. 2007, 76, 387-417
4. Montell C. The TRP superfamily of cation channels. Sci. STKE. 2005, (272), re3.
5. Ständer S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V, Brzoska T, Lippert U, Henz BM, Luger TA, Metze D, Steinhoff M. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 2004, 13(3), 129-39
6. Bodó E, Kovács I, Telek A, Varga A, Paus R, Kovács L, Bíró T. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J. Invest. Dermatol. 2004, 123(2), 410-3
7. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000, 129(2), 227-30
8. Caterina MJ, Julius D.The vanilloid receptor, a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001, 24, 487-517
9. Papoiu AD, Yosipovitch G.Topical capsaicin. The fire of a 'hot' medicine is reignited. Expert. Opin. Pharmacother. 2010, 11(8), 1359-71
10. Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, Nowak P, Voegel JJ, Buddenkotte J, Steinhoff M. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J. Invest. Dermatol. 2012, 132(4), 1253-62.
11. Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J. Invest. Dermatol. 2007, 127(3), 654-
12. Lee YM, Kang SM, Chung JH. The role of TRPV1 channel in aged human skin. J. Dermatol. Sci. 2012, 65(2), 81-5
13. Bíró T, Bodó E, Telek A, Géczy T, Tychsen B, Kovács L, Paus R. Hair cycle control by vanilloid receptor-1 (TRPV1), evidence from TRPV1 knockout mice. J. Invest. Dermatol. 2006, 126(8), 1909-12
14. Bodó E, Bíró T, Telek A, Czifra G, Griger Z, Tóth BI, Mescalchin A, Ito T, Bettermann A, Kovács L, Paus R. A hot new twist to hair biology, involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am. J. Pathol. 2005, 166(4), 985-98.
15. Yun JW, Seo JA, Jang WH, Koh HJ, Bae IH, Park YH, Lim KM. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models. J. Invest. Dermatol. 2011, 131(7), 1576-9.
16. Tóth BI, Dobrosi N, Dajnoki A, Czifra G, Oláh A, Szöllosi AG, Juhász I, Sugawara K, Paus R, Bíró T. Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J. Invest. Dermatol. 2011, 131(5), 1095-104.
17. Yosipovitch G, Mengesha Y, Facliaru D, David M. Topical capsaicin for the treatment of acute lipodermatosclerosis and lobular panniculitis. J. Dermatolog. Treat. 2005, 16(3), 178-80.
18. Xiao B, Patapoutian A. Scratching the surface, a role of painsensing TRPA1 in itch. Nat. Neurosci. 2011, 14(5), 540-2.
19. Shim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY, Lee CH, Kim M, Oh U. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J. Neurosci.2007, 27 (9), 2331-7.
20. Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat. Neurosci. 2011; 14 (5), 595-602.
21. Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI, Han SK. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(27), 11330-5.
22. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J. Am. Acad. Dermatol. 2001, 44(3), 471-8.
23. Ellis CN, Berberian B, Sulica VI, et. al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J. Am. Acad. Dermatol. 1993, 29(3), 438-42.
24. Hopps JJ, Dunn WR, Randall MD. Vasorelaxation to capsaicin and its effects on calcium influx in arteries. Eur. J. Pharmacol. 2012, 681(1-3), 88-93.
25. Wang JP, Hsu MF, Hsu TP, Teng CM. Antihemostatic and antithrombotic effects of capsaicin in comparison with aspirin and indomethacin. Thromb. Res. 1985, 37(6), 669-79.
26. Kantor GR, Resnik KS. Treatment of lichen simplex chronicus with topical capsaicin cream. Acta. Derm. Venereol. 1996, 76(2), 161.
27. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J. Am. Acad. Dermatol. 2001, 44(3), 471-8.
28. Yun JW, Seo JA, Jeong YS, Bae IH, Jang WH, Lee J, Kim SY, Shin SS, Woo BY, Lee KW, Lim KM, Park YH. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J. Dermatol. Sci. 2011, 62(1), 8-15.
29. Lim KM, Park YH. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch. Pharm. Res. 2012, 35(3), 393-6.
30. Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, Nowak P, Voegel JJ, Buddenkotte J, Steinhoff M. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J. Invest. Dermatol. 2012, 132(4), 1253-62.
31. Axelsson HE, Minde JK, Sonesson A, Toolanen G, Högestätt ED, Zygmunt PM. Transient receptor potential vanilloid 1, vanilloid 2 and melastatin 8 immunoreactive nerve fibers in human skin from individuals with and without Norrbottnian congenital insensitivity to pain. Neuroscience. 2009, 162(4), 1322-32.
32. Asakawa M, Yoshioka T, Matsutani T, Hikita I, Suzuki M, Oshima I, Tsukahara K, Arimura A, Horikawa T, Hirasawa T, Sakata T. Association of a mutation in TRPV3 with defective hair growth in rodents. J. Invest. Dermatol. 2006 126, 2664-2672.
33. Cheng X, Jin J, Hu L, Shen D, Dong XP, Samie MA, Knoff J, Eisinger B, Liu ML, Huang SM, Caterina MJ, Dempsey P, Michael LE, Dlugosz AA, Andrews NC, Clapham DE, Xu H. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell. 2010, 141(2), 331-43.
34. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy M, Story GM, Patapoutian A. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science. 2005, 307(5714), 1468-72.
35. Steinhoff M, Bíró T. A TR(I)P to pruritus research, role of TRPV3 in inflammation and itch. J. Invest. Dermatol. 2009, 129(3), 531-5.
36. Yoshioka T, Imura K, Asakawa M, Suzuki M, Oshima I, Hirasawa T, Sakata T, Horikawa T, Arimura A. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. J. Invest. Dermatol. 2009, 129(3), 714-22.
37. Lin Z, Chen Q, Lee M, Cao X, Zhang J, Ma D, Chen L, Hu X, Wang H, Wang X, Zhang P, Liu X, Guan L, Tang Y, Yang H, Tu P, Bu D, Zhu X, Wang K, Li R, Yang Y. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am. J. Hum. Genet. 2012, 90(3), 558-64.
38. Hu HZ, Xiao R, Wang C, Gao N, Colton CK, Wood JD, Zhu MX. Potentiation of TRPV3 channel function by unsaturated fatty acids. J. Cell. Physiol. 2006, 208(1), 201-12.
39. Wingfield C. Skin care in the older person, a focus on the use of emollients. Br. J. Community. Nurs. 2011, 16(10), 470-6, 478.
40. Yamamoto-Kasai E, Imura K, Yasui K, Shichijou M, Oshima I, Hirasawa T, Sakata T, Yoshioka T. TRPV3 as a Therapeutic Target for Itch. J. Invest. Dermatol. 2012, 132(8), 2109-12.
41. Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J. Biol. Chem 2004, 279, 21569-21575.
42. Sokabe T, Tominaga M. The TRPV4 cation channel, A molecule linking skin temperature and barrier function. Commun. Integr. Biol. 2010, 3(6), 619-21.
43. Kida N, Sokabe T, Kashio M, Haruna K, Mizuno Y, Suga Y, Nishikawa K, Kanamaru A, Hongo M, Oba A, Tominaga M.Importance of transient receptor potential vanilloid 4 (TRPV4) in epidermal barrier function in human skin keratinocytes. Pflugers. Arch. 2012, 463(5), 715-25.
44. Lehen'Kyi V, Raphaël M, Prevarskaya N. The role of the TRPV6 channel in cancer. J. Physiol. 2012, 590(Pt 6), 1369-76.
45. Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR. Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab. Invest. 2002, 82(12), 1755-64.
46. Lehen'Kyi V, Beck B, Polakowska R, Charveron M, Bordat P, Skryma R, Prevarskaya N. TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes. J. Biol. Chem. 2007, 282(31), 22582-91.
47. Denda M, Tsutsumi M. Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. Adv. Exp. Med. Biol. 2011, 704, 847-60
48. Lehen'Kyi V, Vandenberghe M, Belaubre F, Julié S, Castex-Rizzi N, Skryma R, Prevarskaya N Acceleration of keratinocyte differentiation by transient receptor potential vanilloid (TRPV6) channel activation. J. Eur. Acad. Dermatol. Venereol. 2011, 25 Suppl 1, 12-8.
49. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007, 445(7130), 866-73
50. Proksch E, Brandner JM, Jensen JM. The skin, an indispensable barrier. Exp. Dermatol. 2008, 17(12), 1063-72.
51. Atoyan R, Shander D, Botchkareva NV. Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J. Invest. Dermatol. 2009, 129(9), 2312-5.
52. Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL. TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J. Neurosci. 2009, 29(15), 4808-19.
53. Sikand P, Dong X, LaMotte RH. BAM8-22 peptide produces itch and nociceptive sensations in humans independent of histamine release. J. Neurosci. 2011, 31(20), 7563-7.
54. Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, Ru F, Guan Y, Weng HJ, Geng Y, Undem BJ, Kollarik M, Chen ZF, Anderson DJ, Dong X. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009, 139(7), 1353-65.
55. Oehler B, Scholze A, Schaefer M, Hill K. TRPA1 is functionally expressed in melanoma cells but is not critical for impaired proliferation caused by allyl isothiocyanate or cinnamaldehyde. Naunyn. Schmiedebergs. Arch. Pharmacol. 2012, 385(6), 555-63.
56. Hammock L, Cohen C, Carlson G, Murray D, Ross JS, Sheehan C, Nazir TM, Carlson JA. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J. Cutan. Pathol. 2006 Sep;33(9), 599-607.
57. Devi S, Kedlaya R, Maddodi N, Bhat KM, Weber CS, Valdivia H, Setaluri V. Calcium homeostasis in human melanocytes, role of transient receptor potential melastatin 1 (TRPM1) and its regulation by ultraviolet light. Am. J. Physiol. Cell. Physiol. 2009, 297(3), C679-87.
58. Guo H, Carlson JA, Slominski A. Role of TRPM in melanocytes and melanoma. Exp. Dermatol. 2012, 21(9), 650-4.
59. Oancea E, Wicks NL. TRPM1, new trends for an old TRP. Adv. Exp. Med. Biol. 2011, 704, 135-45.
60. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ. Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol. 2001, 19(2), 568-76.
61. Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum. Pathol. 2000, 31(11), 1346-56.
62. Devi S, Kedlaya R, Maddodi N, Bhat KM, Weber CS, Valdivia H, Setaluri V. Calcium homeostasis in human melanocytes, role of transient receptor potential melastatin 1 (TRPM1) and its regulation by ultraviolet light. Am. J. Physiol. Cell. Physiol. 2009, 297(3), C679-87.
63. Freichel M, Almering J, Tsvilovskyy V. The Role of TRP Proteins in Mast Cells. Front. Immunol. 2012, 3, 150.
64. Mathar I, Vennekens R, Meissner M, Kees F, Van der Mieren G, Camacho Londoño JE, Uhl S, Voets T, Hummel B, van den Bergh A, Herijgers P, Nilius B, Flockerzi V, Schweda F, Freichel M. Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice. J. Clin. Invest. 2010, 120(9), 3267-79.
65. McCoy DD, Knowlton WM, McKemy DD. Scraping through the ice, uncovering the role of TRPM8 in cold transduction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300(6), R1278-87.
66. Frölich M, Enk A, Diepgen TL, Weisshaar E. Successful treatment of therapy-resistant pruritus in lichen amyloidosis with menthol. Acta. Derm. Venereol. 2009, 89(5), 524-6.
67. Han JH, Choi HK, Kim SJ. Topical TRPM8 Agonist (Icilin) Relieved Vulva Pruritus Originating From Lichen Sclerosus et Atrophicus. Acta. Derm. Venereol. 2012, 92(5), 561-562.
68. Patel T, Ishiuji Y, Yosipovitch G. Menthol, a refreshing look at this ancient compound. J. Am. Acad. Dermatol. 2007, 57(5), 873-8.
69. Yamamura H, Ugawa S, Ueda T, Morita A, Shimada S. TRPM8 activation suppresses cellular viability in human melanoma. Am. J. Physiol. Cell. Physiol. 2008, 295(2), C296-301.
70. Leuner K, Kraus M, Woelfle U, Beschmann H, Harteneck C, Boehncke WH, Schempp CM, Müller WE. Reduced TRPC channel expression in psoriatic keratinocytes is associated with impaired differentiation and enhanced proliferation. PLoS. One. 2011, 6(2), e14716.
71. Garrison SR, Dietrich A, Stucky CL. TRPC1 contributes to lighttouch sensation and mechanical responses in low-threshold cutaneous sensory neurons. J. Neurophysiol. 2012, 107(3), 913-22.
72. Beck B, Lehenkyi V, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, Skryma R. TRPC channels determine human keratinocyte differentiation, new insight into basal cell carcinoma. Cell. Calcium. 2008, 43(5), 492-505.
73. Pani B, Singh BB. Darier's disease, a calcium-signaling perspective. Cell. Mol. Life. Sci. 2008, 65(2), 205-11.
74. Pani B, Cornatzer E, Cornatzer W, Shin DM, Pittelkow MR, Hovnanian A, Ambudkar IS, Singh BB. Up-regulation of transient receptor potential canonical 1 (TRPC1) following sarco(endo)plasmic reticulum Ca2+ ATPase 2 gene silencing promotes cell survival, a potential role for TRPC1 in Darier's disease. Mol. Biol. Cell. 2006, 17(10), 4446-58.
75. Ma HT, Beaven MA. Regulators of Ca(2+) signaling in mast cells, potential targets for treatment of mast cell-related diseases? Adv. Exp. Med. Biol. 2011, 716, 62-90.
76. Müller M, Essin K, Hill K, Beschmann H, Rubant S, Schempp CM, Gollasch M, Boehncke WH, Harteneck C, Müller WE, Leuner K. Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J. Biol. Chem. 2008, 283(49), 33942-54.
77. Huyke C, Reuter J, Rödig M, Kersten A, Laszczyk M, Scheffler A, Nashan D, Schempp C.Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J. Dtsch. Dermatol. Ges. 2009, 7(2), 128-33.
78. Englert C, Hughes B. A review of actinic keratosis for the nurse practitioner, diagnosis, treatment, and clinical pearls. J. Am. Acad. Nurse. Pract. 2012, 24(5), 290-6.
79. Huyke C, Reuter J, Rödig M, Kersten A, Laszczyk M, Scheffler A, Nashan D, Schempp C.Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J. Dtsch. Dermatol. Ges. 2009, 7(2), 128-33.
80. Woelfle U, Laszczyk MN, Kraus M, Leuner K, Kersten A, SimonHaarhaus B, Scheffler A, Martin SF, Müller WE, Nashan D, Schempp CM. Triterpenes promote keratinocyte differentiation in. vitro, ex vivo and in. vivo, a role for the transient receptor potential canonical (subtype) 6. J. Invest. Dermatol. 2010; 130 (1), 113-23.
81. Slominski A. Cooling skin cancer, menthol inhibits melanoma growth. Focus on TRPM8 activation suppresses cellular viability in human melanoma. Am. J. Physiol. Cell. Physiol. 2008, 295(2), C293-5.
82. Xu H, Delling M, Li L, Dong X, Clapham DE. Activating mutation in a mucolipin transient receptor potential channel leads to melanocyte loss in varitint-waddler mice. Proc. Natl. Acad. Sci. USA. 2007, 104, 18321-18326.